MabVax Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch MBVXQ and buy or sell other stocks, ETFs, and their options commission-free!

About MBVXQ

MabVax Therapeutics Holdings, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. The company was founded in 1988 and is headquartered in Clinton, AR. 

CEO
John David Hansen
CEOJohn David Hansen
Employees
Employees
Headquarters
Clinton, Arkansas
HeadquartersClinton, Arkansas
Founded
2014
Founded2014
Employees
Employees

MBVXQ Key Statistics

Market cap
216.90K
Market cap216.90K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
976.70
Average volume976.70
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.139
52 Week high$0.139
52 Week low
$0.0037
52 Week low$0.0037

Stock Snapshot

With a market cap of 216.9K, MabVax Therapeutics(MBVXQ) trades at $0.02.

On 2026-07-22, MabVax Therapeutics(MBVXQ) stock opened at —, reached a high of —, and a low of —.

MabVax Therapeutics(MBVXQ) shares are trading with a volume of 0, against a daily average of 976.7.

In the last year, MabVax Therapeutics(MBVXQ) shares hit a 52-week high of $0.14 and a 52-week low of $0.00.

In the last year, MabVax Therapeutics(MBVXQ) shares hit a 52-week high of $0.14 and a 52-week low of $0.00.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.